liver
fibrosi
hepat
respons
insult
character
accumul
extracellular
matrix
protein
underli
caus
treat
elimin
diseas
progress
may
lead
sever
clinic
complic
includ
hepatocellular
carcinoma
even
death
thu
detect
stage
followup
liver
fibrosi
main
issu
prognosi
treatment
patient
chronic
liver
diseas
recent
year
new
advanc
mass
spectrometrybas
proteom
technolog
protein
fraction
techniqu
improv
protein
identif
well
protein
quantif
mani
differ
sampl
diseas
includ
liver
fibrosi
particular
fibrinogen
chain
specif
serum
level
kda
fragment
fibrinogen
cchain
shown
alter
sever
hepat
etiolog
fact
result
reproduc
differ
laboratori
recent
mark
downregul
protein
fragment
also
describ
initi
stage
liver
fibrosi
chapter
describ
potenti
role
fibrinogen
chain
particularli
kda
fragment
fibrinogen
cchain
circul
marker
liver
fibrosi
liver
largest
organ
bodi
locat
upperright
region
abdomin
caviti
compris
four
differ
lobe
organ
dual
blood
suppli
hepat
arteri
portal
vein
hepat
arteri
provid
oxygen
necessari
achiev
differ
vital
function
portal
vein
come
intestin
detoxifi
organ
blood
flow
converg
form
hepat
vein
final
drain
inferior
vena
cava
sever
cell
type
compos
organ
classifi
parenchym
nonparenchym
cell
hepat
stellat
cell
hsc
kupffer
cell
hepatocyt
relev
cell
type
latter
howev
princip
cell
type
liver
occupi
around
volum
liver
gener
hepatocyt
execut
mani
differ
function
includ
protein
synthesi
bile
synthesi
secret
toxin
metabol
etc
invent
j
j
thomson
function
separ
identifi
even
quantifi
molecul
base
masstocharg
ratio
mz
howev
molecul
must
firstli
convert
gaseou
ion
mass
spectromet
consist
three
basic
element
ion
sourc
sampl
ioniz
exampl
compon
electrospray
ioniz
esi
matrixassist
laser
desorptionion
maldi
surfaceenhanc
laser
desorptionion
seldi
mass
analyz
molecul
separ
accord
masstocharg
ratio
mz
exampl
compon
time
flight
tof
quadrupol
ion
trap
among
other
ion
detector
use
detect
record
rel
abund
charg
molecul
altern
splice
biolog
process
multipl
mrna
subsequ
protein
gener
gene
basic
dna
transcrib
premrna
contain
intron
exon
subsequ
matur
mrna
form
total
partial
retent
exon
creat
divers
panel
mrna
singl
premrna
phenomenon
enhanc
proteom
divers
function
capac
gene
coagul
physiolog
process
fibrinogen
convert
fibrin
action
thrombin
cleavag
lead
appear
fibrin
clot
turn
liquid
blood
thicken
mass
fibrinolysi
mechan
fibrin
clot
broken
action
plasmin
physiolog
function
prevent
growth
blood
clot
reduc
potenti
side
effect
ha
hyaluron
acid
one
compon
extracellular
matrix
ecm
serum
level
proven
good
correl
sever
liver
diseas
fact
excel
tool
identifi
late
stage
liver
fibrogenesi
howev
use
detect
earli
fibrot
stage
hcv
hepat
c
viru
one
main
caus
liver
fibrosi
cirrhosi
worldwid
main
indic
liver
transplant
howev
recent
advanc
drug
develop
allow
obtain
better
highli
effect
drug
predict
reduc
clinic
complic
caus
viru
liver
biopsi
recent
liver
biopsi
gold
standard
method
stage
liver
fibrosi
invas
procedur
involv
remov
small
sampl
liver
tissu
histolog
examin
determin
underli
caus
sever
liver
diseas
mz
ratio
masstocharg
ratio
relat
mass
molecul
charg
number
z
chapter
molecul
analyz
ms
protein
addit
sinc
mani
ion
carri
charg
mz
ratio
often
consid
molecular
weight
compound
malditoftof
ms
proteom
approach
allow
analysi
identif
even
quantif
sever
biomolecul
includ
protein
use
biomark
discoveri
nash
nonalcohol
steatohepat
one
advanc
consequ
nonalcohol
fatti
liver
diseas
nafld
subsequ
nash
lead
cirrhosi
liver
failur
even
hcc
term
preval
phenomenon
increas
western
societi
last
decad
due
sedentari
habit
unhealthi
diet
metabol
syndrom
basic
character
fat
accumul
liver
caus
inflamm
damag
biolog
mechan
enhanc
proteom
divers
addit
play
pivot
role
sever
cellular
process
posttransl
modif
ptm
includ
modif
gener
protein
synthesi
phosphoryl
methyl
proteolysi
exampl
wide
varieti
modif
one
commonli
use
classif
assess
chronic
hepat
liver
biopsi
specimen
basic
liver
fibrosi
stage
zero
four
fibrosi
correspond
fibrosi
stage
minim
portal
fibrosi
would
stage
periport
fibrosi
fibrosi
beyond
portal
tract
make
septum
final
cirrhosi
highthroughput
proteom
approach
similar
malditof
also
use
biomark
discoveri
howev
incorpor
solidphas
chromatographi
reduc
complex
biolog
sampl
protein
allow
better
select
protein
interest
transform
growth
factor
beta
mainli
produc
kupffer
cell
import
cytokin
promot
wound
heal
repair
induc
apoptosi
hepatocyt
activ
hsc
tissu
inhibitor
metalloproteinas
produc
sever
type
hepat
cell
inhibit
degrad
newli
form
collagen
fibril
mmp
also
highli
upregul
fibrogen
process
liver
fibrosi
dynam
revers
woundheal
process
character
accumul
extracellular
matrix
protein
ecm
respons
chronic
injuri
batal
brenner
despit
remark
regen
capac
liver
underli
caus
treat
elimin
chronic
liver
injuri
lead
cirrhosi
hepatocellular
carcinoma
liver
failur
even
death
batal
brenner
lee
friedman
forner
et
al
schuppan
kim
tsochatzi
et
al
mani
differ
caus
contribut
liver
fibrosi
howev
main
etiolog
develop
countri
alcohol
liver
diseas
ald
cholestasi
chronic
hepat
b
viru
hbv
c
viru
hcv
infect
recent
nonalcohol
steatohepat
nash
schuppan
kim
friedman
knowledg
extent
hepat
fibrosi
critic
defin
establish
prognosi
progress
well
make
treatment
decis
howev
clinic
practic
earli
detect
liver
fibrosi
mani
case
rel
complex
sinc
detect
clinic
symptom
hepat
decompens
occur
within
week
month
even
year
onset
injuri
hernandezgea
friedman
fact
studi
point
patient
liver
diseas
asymptomat
year
clinic
complic
appear
heidelbaugh
bruderli
thu
prompt
detect
hepat
fibrogenesi
major
import
prognosi
treatment
patient
chronic
liver
diseas
present
liver
biopsi
remain
gold
standard
method
stage
liver
fibrosi
fernandezvaro
jimenez
nevertheless
procedur
must
perform
train
physician
due
invas
addit
may
involv
sever
clinic
complic
includ
pain
hemorrhag
potenti
morbid
even
death
furthermor
small
amount
specimen
obtain
liver
biopsi
might
repres
fibrosi
stage
whole
organ
due
heterogen
fibrosi
moreov
interobserv
variabl
also
taken
account
liver
biopsi
allow
fibrosi
progressionrevers
followup
castera
pinzani
bedossa
et
al
fernandezvaro
jimenez
reason
mani
effort
made
last
decad
find
new
noninvas
procedur
altern
liver
biopsi
effort
essenti
focus
develop
imag
techniqu
identifi
new
circul
biomark
et
al
castera
et
al
crespo
et
al
despit
option
sever
import
advantag
includ
noninvas
easi
sequenti
followup
diseas
latter
allow
better
access
alrawashdeh
crnogoracjurcev
ideal
marker
liver
fibrosi
specif
highli
sensit
discrimin
differ
stage
liver
fibrosi
etiolog
also
easi
measur
econom
well
reproduc
addit
vari
inflamm
metabol
disord
use
monitor
fibrosi
progressionregress
baranova
et
al
final
biomark
also
abl
discrimin
underli
caus
liver
diseas
nonetheless
current
marker
fulfil
criteria
watkin
howev
advanc
made
field
allow
identif
new
potenti
promis
biolog
marker
addit
combin
sever
serum
marker
appear
anoth
interest
strategi
discrimin
differ
stage
liver
fibrosi
sebastiani
et
al
castera
crespo
et
al
fact
one
wellknown
algorithm
enhanc
liver
fibrosi
elf
combin
serum
level
three
differ
direct
biolog
marker
ha
piiinp
algorithm
develop
intern
multicent
studi
includ
cohort
patient
differ
hepat
etiolog
rosenberg
et
al
age
initi
includ
algorithm
final
exclud
valid
elf
tool
fact
elf
highli
accur
detect
patient
signific
fibrosi
cirrhosi
martinez
et
al
crespo
et
al
howev
sever
studi
report
lower
diagnost
capac
earli
mild
stage
hepat
fibrosi
valu
obtain
fibrot
patient
similar
healthi
subject
martinez
et
al
lichtinghagen
et
al
fact
common
trend
mani
noninvas
marker
algorithm
thu
discrimin
earli
stage
liver
fibrosi
remain
challeng
diseas
view
fact
hepatocyt
predomin
cell
type
liver
respons
synthesi
intrahepat
extrahepat
protein
includ
plasma
coagul
protein
prothrombin
fibrinogen
tennent
et
al
feasibl
think
even
subtl
chang
liver
architectur
incur
abnorm
protein
synthesi
detect
bloodstream
thu
circul
protein
one
studi
area
research
recent
advanc
mass
spectrometrybas
proteom
technolog
protein
fraction
techniqu
improv
protein
identif
well
protein
quantif
mani
differ
sampl
diseas
aebersold
mann
camerini
mauri
particular
thank
technic
advanc
chang
mani
abund
nonabund
protein
detect
also
protein
fragment
releas
circul
hortin
context
studi
demonstr
alter
circul
serum
fibrinogen
fragment
human
fibrinogen
one
abund
protein
blood
play
pivot
role
coagul
cascad
mosesson
et
al
davalo
akassogl
structur
kda
acut
phase
glycoprotein
synthes
liver
compris
two
symmetr
set
three
differ
chain
known
predomin
chain
longest
polypeptid
chain
contain
residu
weigh
kda
kda
kda
chain
consist
amino
acid
respect
howev
fibrinogen
chain
heterogen
result
altern
splice
posttransl
modif
even
proteolyt
degrad
herrick
et
al
nterminu
chain
bound
disulfid
knot
form
central
e
domain
region
chain
present
small
peptid
sequenc
known
fibrinopeptid
b
respect
crucial
prevent
convers
fibrinogen
fibrin
opposit
end
cterminu
fragment
chain
togeth
portion
chain
constitut
outer
domain
end
peptid
sequenc
chain
call
domain
form
freeswim
appendag
doolittl
interact
central
region
molecul
even
domain
intermolecular
interact
fibrin
polymer
addit
region
suscept
cleav
fibrinogen
sever
proteas
includ
plasmin
releas
system
circul
degrad
cesarmanmau
hajjar
howev
fragment
region
detect
dissolut
use
potenti
biomark
mani
diseas
includ
liver
fibrosi
physiolog
condit
coagul
fibrinolysi
mechan
precis
regul
mani
differ
element
cesarmanmau
hajjar
due
differ
stimuli
fibrinogen
convert
fibrin
thrombin
afterward
fibrin
clot
broken
order
prevent
excess
clot
format
subsequ
blood
vessel
blockag
sever
factor
involv
complex
process
although
plasmin
basic
enzym
lyse
fibrin
mesh
differ
locat
gener
fibrinogen
fragment
differ
size
cesarmanmau
hajjar
result
fragment
releas
circul
subsequ
degrad
proteas
howev
process
acceler
liver
injuri
takahashi
et
al
furthermor
also
well
establish
breakdown
fragment
exert
direct
effect
tissu
repair
herrick
et
al
therefor
possibl
solubl
fragment
releas
bloodstream
even
molecul
relat
coagul
fibrinolysi
process
could
differenti
express
liver
diseas
use
biomark
hepat
fibrosi
nevertheless
seem
depend
etiolog
mechan
degrad
even
cleavag
site
could
differ
fact
studi
report
conform
chang
occur
fibrinogen
molecul
moder
alcohol
consumpt
gorinstein
et
al
also
well
known
lower
concentr
serum
fibrinogen
level
patient
moder
alcohol
consumpt
sierksma
et
al
addit
investig
suggest
moder
consumpt
entail
chang
fibrinolysi
van
gold
et
al
despit
studi
describ
presenc
clear
chang
mechan
dimmitt
et
al
well
establish
serum
fibrinogen
level
remain
unalt
patient
stabl
liver
diseas
howev
behavior
differ
patient
advanc
hepat
fibrosi
de
maat
et
al
fact
sever
studi
report
fibrinogen
level
usual
diminish
patient
even
though
cirrhot
patient
may
present
fibrinogen
serum
concentr
within
normal
rang
pluta
et
al
note
childpugh
c
cirrhot
patient
show
lowest
serum
level
probabl
due
overal
reduct
protein
synthesi
stage
furthermor
dysfibrinogenemia
also
often
observ
patient
acut
liver
failur
mistri
jain
therefor
serum
fibrinogen
alter
seem
mainli
found
advanc
liver
diseas
specif
case
acut
liver
failur
earli
alter
observ
earli
stage
liver
fibrosi
associ
clear
inflammatori
process
context
analysi
fragmentom
also
call
peptidom
may
play
pivot
role
detect
fragmentom
approach
analysi
entir
set
tini
peptid
compon
fruit
degrad
abund
protein
serum
plasma
hortin
fact
report
fragmentom
modif
may
better
indic
inflamm
even
organ
injuri
intact
protein
regard
fibrinogen
sever
molecular
fragment
chain
cleav
releas
bloodstream
due
sever
stimuli
indepth
discuss
chain
fragment
outsid
scope
chapter
howev
chain
fragment
particularli
interest
due
rapid
alter
earli
stage
liver
fibrosi
et
al
inde
recent
studi
use
ms
technolog
identifi
alter
fragment
fibrinogen
chain
kda
ctermin
fragment
fibrinogen
chain
one
frequent
describ
present
determin
blood
ethanol
level
perform
recent
alcohol
intak
hand
sever
biochem
marker
diagnosi
ald
among
carbohydratedefici
transferrin
cdt
gammaglutamyltransferas
ggt
commonli
use
anton
et
al
howev
heavi
drinker
alter
observ
blood
ggt
serum
concentr
within
standard
rang
matsuda
et
al
first
studi
identifi
describ
clear
alter
express
fibrinogen
fragment
ald
nomura
et
al
studi
fibrinogen
cchain
fragment
detect
selditofm
serum
level
circul
fragment
found
downregul
admiss
significantli
increas
month
abstin
alcohol
fig
thu
investig
demonstr
peptid
allow
monitor
potenti
relaps
well
alcohol
abstin
addit
note
circul
biomark
abl
detect
heavi
drinker
includ
patient
normal
ggt
serum
level
unalt
case
therebi
establish
diagnost
valu
ald
sogawa
et
al
highlight
promis
role
potenti
biomark
alcohol
intak
howev
number
patient
includ
studi
low
vast
major
men
moreov
consum
g
alcohol
per
day
minimum
year
indic
subject
like
advanc
rather
earli
liver
fibrosi
nonetheless
result
valid
year
later
group
use
malditoftof
ms
approach
sogawa
et
al
studi
three
alter
peptid
also
detect
malditoftof
ms
serum
sampl
heavi
drinker
identifi
fragment
fibrinopeptid
mz
phosphoryl
fibrinopeptid
mz
fibrinogen
cchain
mz
later
sogawa
et
al
perform
anoth
studi
group
healthi
subject
patient
differ
liver
diseas
includ
ald
basic
investig
focus
quantit
determin
kda
fragment
fibrinogen
chain
use
malditofm
method
stableisotop
dilut
mass
spectrometri
sidm
wide
use
ms
approach
allow
discoveri
quantit
determin
potenti
circul
diseas
biomark
abl
determin
kda
fibrinogen
fragment
accur
ordinari
ms
ultim
noda
et
al
develop
quantit
enzymelink
immunosorb
assay
elisa
abl
perform
access
afford
quantif
analysi
determin
kda
fragment
level
serum
sampl
patient
ald
healthi
subject
howev
take
account
complex
work
specif
peptid
fragment
whole
protein
techniqu
character
valid
use
sidm
approach
show
good
correl
elisa
outcom
fig
later
studi
focus
identif
earli
circul
serum
biomark
activ
fibrogenesi
et
al
also
identifi
kda
fragment
fibrinogen
cchain
selditofm
techniqu
fact
investig
took
advantag
faster
recurr
hepat
fibrosi
usual
occur
hcv
patient
submit
liver
transplant
lt
mark
downregul
fragment
detect
serum
sampl
ten
hcvposit
patient
submit
month
lt
surgeri
compar
nine
lt
patient
without
hcvrna
recurr
also
underw
antivir
treatment
surgeri
note
month
lt
patient
show
evid
hepat
fibrosi
addit
patient
underw
liver
biopsi
year
lt
forti
percent
cohort
fibrosi
stage
lower
two
accord
scheuer
classif
scheuer
indic
kda
fragment
fibrinogen
cchain
seem
alter
long
histolog
evid
avail
therebi
enhanc
relev
biomark
earli
fibrogen
process
studi
hcv
lt
patient
also
analyz
order
valid
result
obtain
outcom
confirm
fragment
behav
earli
serum
biomark
fibrosi
furthermor
kda
peptid
also
determin
serum
sampl
eight
hcv
nonlt
patient
differ
degre
fibrosi
result
ident
fig
serum
level
kda
fragment
fibrinogen
cchain
also
evalu
sampl
patient
etiolog
hcv
infect
ald
nash
hbv
autoimmun
hepat
ah
cryptogen
liver
damag
et
al
fig
result
investig
line
obtain
hcvinfect
patient
ald
patient
sinc
absenc
kda
fragment
confirm
subject
therefor
lack
kda
peptid
common
find
patient
activ
fibrogen
process
regardless
whether
consequ
alter
lipid
metabol
alcohol
intak
viral
infect
fig
addit
contrast
previous
describ
biomark
liver
fibrosi
kda
fragment
fibrinogen
cchain
could
use
identifi
subject
activ
fibrogen
process
includ
earli
stage
liver
damag
rather
stage
fibrot
patient
mz
mz
fig
lack
kda
fibrinogen
cchain
fragment
fibrot
patient
fragment
selditofm
spectra
rang
mz
serum
sampl
obtain
healthi
subject
patient
liver
fibrosi
sever
etiolog
includ
nash
ah
hbv
cryptogen
lack
kda
fibrinogen
cchain
fragment
clearli
associ
fibrogenesi
regardless
etiolog
modifi
figur
legend
et
al
cell
regul
serum
stabil
kda
fibrinogen
alpha
cchain
fragment
mechan
kda
fragment
fibrinogen
cchain
diminish
serum
sampl
patient
activ
fibrogen
process
fulli
understood
well
establish
major
regul
fibrinogen
gene
express
fuller
zhang
suggest
mediat
involv
inflammatori
respons
could
respons
alter
serum
content
kda
fragment
patient
liver
fibrosi
test
hypothesi
et
al
recent
expos
cell
human
liver
hepatocellular
carcinoma
cell
line
sever
wellknown
profibrogen
proinflammatori
agent
includ
lipopolysaccharid
angiotensin
ii
apelin
fibronectin
note
abl
reduc
amount
kda
fragment
cell
cultur
medium
cell
associ
downregul
mrna
express
fibrinogen
chain
gene
fga
transcript
correspond
chain
gene
fgb
fgg
respect
fig
first
experiment
data
demonstr
specif
regul
kda
fragment
demograph
variabl
well
preanalyt
condit
major
issu
consid
diagnost
feasibl
biomark
regard
sogawa
et
al
demonstr
gender
age
affect
serum
level
kda
fragment
fig
modifi
factor
interv
venipunctur
serum
separ
result
indic
sampl
process
condit
accur
establish
order
avoid
analyt
misinterpret
present
studi
specif
address
estim
strength
kda
fibrinogen
cchain
fragment
prognost
diagnost
tool
liver
diseas
hand
take
biomark
research
lab
daili
routin
clinic
diagnost
lab
depend
accur
defin
sensit
specif
posit
predict
valu
neg
predict
valu
indic
earli
fibrogen
activ
also
determin
avail
highthroughput
method
automat
immunoassay
measur
concentr
biolog
fluid
final
neither
known
whether
kda
fragment
specif
biomark
liver
fibrosi
regard
studi
perform
pang
et
al
show
ms
spectra
patient
sever
acut
respiratori
syndrom
sar
outbreak
period
display
diminut
intens
kda
fragment
comparison
nonsar
patient
selditofm
proteom
techniqu
also
wide
use
investig
alter
express
kda
fragment
patholog
includ
differ
type
neoplasia
sever
experiment
data
suggest
fragment
could
biomark
condit
instanc
diminut
mz
intens
fragment
describ
breast
ovarian
prostat
nonsmal
cell
lung
cancer
engwegen
et
al
belluco
et
al
contrast
increas
intens
found
colorect
cancer
pancreat
adenocarcinoma
koopmann
et
al
engwegen
et
al
note
none
investig
identifi
amino
acid
sequenc
protein
peak
howev
presum
kda
fragment
fibrinogen
cchain
sinc
sampl
process
ms
method
similar
investig
amino
acid
sequenc
identif
perform
therefor
quit
plausibl
kda
fragment
fibrinogen
cchain
also
use
biomark
type
neoplast
diseas
last
decad
invas
techniqu
option
stage
liver
fibrosi
recent
technolog
advanc
allow
develop
new
imag
techniqu
identif
novel
circul
protein
marker
detect
monitor
evolut
liver
diseas
although
mani
circul
biomark
appropri
identif
followup
sever
stage
liver
fibrosi
diagnost
capac
lower
earli
mild
stage
kda
fragment
fibrinogen
cchain
detect
serum
abl
identifi
patient
earli
stage
liver
fibrosi
differ
observ
fibrot
patient
term
age
gender
etiolog
fibrosi
stage
kda
fragment
fibrinogen
cchain
evalu
seem
one
potenti
stimuli
affect
releas
kda
fibrinogen
peptid
